Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort

"Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM"

Detalles Bibliográficos
Autores: Berenguer, Juan, Arribas López, José Ramón, González García, Juan Julián
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/705072
Acceso en línea:http://hdl.handle.net/10486/705072
https://dx.doi.org/10.1016/j.cmi.2021.06.023
Access Level:acceso abierto
Palabra clave:COVID-19
HIV
SARS-CoV-2
Serology
Seroprevalence
Medicina
id ES_48b29181fbbdae7af30195e06bd3deec
oai_identifier_str oai:repositorio.uam.es:10486/705072
network_acronym_str ES
network_name_str España
repository_id_str
spelling Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network CohortBerenguer, JuanArribas López, José RamónGonzález García, Juan JuliánCOVID-19HIVSARS-CoV-2SerologySeroprevalenceMedicina"Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM"Objectives: We aimed to assess the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and factors associated with seropositivity and asymptomatic coronavirus disease 2019 (COVID-19) among people with HIV (PWH). Methods: This was a cross-sectional study carried out within the cohort of the Spanish HIV Research Network. Participants were consecutive PWH with plasma collected from 1st April to 30th September 2020. We determined SARS-CoV-2 antibodies (Abs) in plasma. Illness severity (NIH criteria) was assessed by a review of medical records and, if needed, participant interviews. Multivariable logistic regression analysis was used to identify predictors of seropositivity among the following variables: sex, age, country of birth, education level, comorbidities (hypertension, chronic heart disease, diabetes mellitus, non-AIDS-related cancer, chronic kidney disease, cirrhosis), route of HIV acquisition, prior AIDS, CD4+ cell count, HIV viral load, nucleoside/nucleotide reverse transcriptase inhibitor (N [t]RTI) backbone, type of third antiretroviral drug, and month of sample collection. Results: Of 1076 PWH (88.0% males, median age 43 years, 97.7% on antiretroviral therapy, median CD4+ 688 cells/mm3, 91.4% undetectable HIV viral load), SARS-CoV-2 Abs were detected in 91 PWH, a seroprevalence of 8.5% (95%CI 6.9–10.3%). Forty-five infections (45.0%) were asymptomatic. Variables independently associated with SARS-CoV-2 seropositivity were birth in Latin American countries versus Spain (adjusted odds ratio (aOR) 2.30, 95%CI 1.41–3.76, p 0.001), and therapy with tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) versus tenofovir alafenamide (TAF)/FTC as the N(t)RTI backbone (aOR 0.49, 95%CI 0.26–0.94, p 0.031). Conclusions: Many SARS-CoV-2 infections among PWH were asymptomatic, and birth in Latin American countries increased the risk of SARS-CoV-2 seropositivity. Our analysis, adjusted by comorbidities and other variables, suggests that TDF/FTC may prevent SARS-CoV-2 infection among PWH.This work was supported by the Instituto de Salud Carlos III (ISCII) (grant number COV20/00108) and the Spanish AIDS Research Network (RD16/0025), which is included in the Spanish I þ D þ I Plan and is co-funded by ISCIII-Subdirección General de Evaluacion and European Funding for Regional Development (FEDER).Elsevier Ltd.Departamento de MedicinaFacultad de Medicina20212021-06-26research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10486/705072https://dx.doi.org/10.1016/j.cmi.2021.06.023reponame:Biblos-e Archivo. Repositorio Institucional de la UAMinstname:Universidad Autónoma de MadridInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:repositorio.uam.es:10486/7050722026-06-23T12:46:27Z
dc.title.none.fl_str_mv Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort
title Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort
spellingShingle Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort
Berenguer, Juan
COVID-19
HIV
SARS-CoV-2
Serology
Seroprevalence
Medicina
title_short Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort
title_full Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort
title_fullStr Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort
title_full_unstemmed Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort
title_sort Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort
dc.creator.none.fl_str_mv Berenguer, Juan
Arribas López, José Ramón
González García, Juan Julián
author Berenguer, Juan
author_facet Berenguer, Juan
Arribas López, José Ramón
González García, Juan Julián
author_role author
author2 Arribas López, José Ramón
González García, Juan Julián
author2_role author
author
dc.contributor.none.fl_str_mv Departamento de Medicina
Facultad de Medicina
dc.subject.none.fl_str_mv COVID-19
HIV
SARS-CoV-2
Serology
Seroprevalence
Medicina
topic COVID-19
HIV
SARS-CoV-2
Serology
Seroprevalence
Medicina
description "Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM"
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-06-26
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10486/705072
https://dx.doi.org/10.1016/j.cmi.2021.06.023
url http://hdl.handle.net/10486/705072
https://dx.doi.org/10.1016/j.cmi.2021.06.023
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier Ltd.
publisher.none.fl_str_mv Elsevier Ltd.
dc.source.none.fl_str_mv reponame:Biblos-e Archivo. Repositorio Institucional de la UAM
instname:Universidad Autónoma de Madrid
instname_str Universidad Autónoma de Madrid
reponame_str Biblos-e Archivo. Repositorio Institucional de la UAM
collection Biblos-e Archivo. Repositorio Institucional de la UAM
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407376191258624
score 15,300724

Similares en LA Referencia